Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD20/CD3 bispecific antibody JS203

A recombinant bispecific antibody targeting both the tumor-associated antigen (TAA) CD20 and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20/CD3 bispecific antibody JS203 binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells. CD20 is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD20/anti-CD3 bispecific antibody JS203
CD20 x CD3 bispecific antibody JS203
Code name:JS 203
JS-203
JS203
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search